Temporal trends and current use of de novo belatacept in kidney transplant recipients in the United States
Geeta Karadkhele(Emory Healthcare), Julien Hogan(Assistance Publique – Hôpitaux de Paris), Thomas C. Pearson(Emory Healthcare), I.R. Badell(Emory University), Charlotte Duneton(Emory Healthcare), Christian P. Larsen(Emory University Hospital), Rouba Garro(Emory University)
Cited by 18
Related Papers
Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
|Nature|1996|1.5k
4-1BB Costimulatory Signals Preferentially Induce CD8+ T Cell Proliferation and Lead to the Amplification In Vivo of Cytotoxic T Cell Responses
|The Journal of Experimental Medicine|1997|802
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Heterologous immunity provides a potent barrier to transplantation tolerance
|Journal of Clinical Investigation|2003|571
Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)
|American Journal of Transplantation|2010|566